

Medicine	Indication	Further Information	Type	LSCMMG planned
Dymista (azelastine/fluticasone) nasal spray	Relief of symptoms of moderate to severe seasonal and perennial allergic rhinitis if monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient	Requested by Consultant ENT, Lancashire Teaching Hospitals NHS Foundation Trust. Would align with proposed guideline based on North West Allergy and Clinical Immunology Network guideline	Major or Moderate, depending on status of NW guideline	December 2024
Acarizax 12 SQ-HDM oral lyophilisate	Treatment of house dust mite sensitisation according to SPC definitions, see: https://www.medicines.org.uk/emc/product/12905	Requested by ENT consultant, ELHT	Major	? NICE expected 12 Feb 2025. Draft guidance does not recommend.
ITULAZAX 12 SQ-Bet sublingual lyophilisate	Treatment of moderate-to-severe allergic rhinitis induced by pollen from the birch homologous group	Requested by Consultant ENT Lancashire Teaching Hospitals NHS Foundation Trust	Major	Uncertain – similar product to Acarizax
Nefopam	For treatment of pain	Pharmacy, BTHTr	Major	December 2024
Infliximab/vedolizumab	For treatment of chemotherapy induced colitis	Requested by Oncology Pharmacist UHMB. Aligns with local cancer network and national guidelines.	Moderate	December 2024
Cytisine	Smoking cessation and reduction of nicotine cravings in smokers who are willing to stop smoking	Requested by Medicines Management Pennine locality and Public Health Specialist Lancashire County Council	Major	January 2025
Dapoxetine	Treatment of premature ejaculation	Requested by sexual health specialist service	Major	January 2025
Diclofenac oral	Initiation of treatment by Rheumatologists	Currently Green (restricted) for short term treatment of post-op pain, renal colic and lithotripsy only	Moderate	February 2025
Semaglutide	For cardiovascular risk reduction	Raised by Fylde ICB locality, discussed at FWG – suggested reviewed	Major	February 2025

